Valuation: Exact Sciences Corporation

Market Cap 2TCr 35TCr 1.75TCr 1.62TCr 1.49TCr 2.83TCr 1,91000Cr 2.88TCr 19TCr 7.58TCr 94TCr 7.52TCr 7.36TCr 3,23500Cr P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 2.16TCr 38TCr 1.89TCr 1.74TCr 1.61TCr 3.05TCr 2,06000Cr 3.1TCr 21TCr 8.18TCr 1,01500Cr 8.11TCr 7.93TCr 3,48800Cr EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
-15.23%+9.18% - - 2TCr
-3.93%-0.19%+110.38%+108.07% 454.58Cr
-3.39%-0.61%+78.17%+203.46% 337.05Cr
+4.20%-1.15%-27.01%-39.95% 204.99Cr
-3.20%-1.86%+126.20%-46.66% 188.87Cr
-2.06%-2.33%+41.63%+175.73% 147.28Cr
+2.01%+0.83%+123.08%-50.04% 90Cr
+6.42%-1.19%-10.08%+43.92% 88Cr
+1.63%-3.18%-36.79%-18.41% 48Cr
+7.05%+1.07%-2.63% - 49Cr
Average -0.65%-0.51%+44.77%+47.01% 178.62Cr
Weighted average by Cap. -8.95%-0.90%+67.94%+80.23%

Financials

2024 2025
Net sales 275.89Cr 4.83TCr 241.32Cr 222.59Cr 205.58Cr 390.08Cr 26TCr 396.64Cr 2.66TCr 1.04TCr 13TCr 1.04TCr 1.01TCr 45TCr 324.7Cr 5.68TCr 284.01Cr 261.97Cr 241.95Cr 459.1Cr 31TCr 466.82Cr 3.13TCr 1.23TCr 15TCr 1.22TCr 1.19TCr 52TCr
Net income -102.89Cr -1.8TCr -90Cr -83Cr -77Cr -145.47Cr -9.81TCr -147.92Cr -991.8Cr -389.48Cr -4.83TCr -386.3Cr -377.9Cr -17TCr -21Cr -363.74Cr -18Cr -17Cr -15Cr -29Cr -1.98TCr -30Cr -200.46Cr -79Cr -977.03Cr -78Cr -76Cr -3.36TCr
Net Debt 173.77Cr 3.04TCr 152Cr 140.2Cr 129.49Cr 245.7Cr 17TCr 249.83Cr 1.68TCr 657.83Cr 8.16TCr 652.46Cr 638.26Cr 28TCr 157.01Cr 2.75TCr 137.34Cr 126.68Cr 117Cr 222Cr 15TCr 225.74Cr 1.51TCr 594.38Cr 7.38TCr 589.53Cr 576.7Cr 25TCr
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA